Serum Institute Of India Chairman Cyrus Poonawalla On How To Succeed In The Vaccines Business: An Interview With PharmAsia News
This article was originally published in PharmAsia News
In a rare interview, Serum Institute of India Chairman Cyrus Poonawalla discusses his determination to keep vaccine prices low for India’s masses and his ongoing battles with multinational pharma companies.
You may also be interested in...
WHO Delists Panacea Biotec's Combination Vaccines From Pre-qualified List; Move Comes A Year After Action Against Sanofi's Shantha Unit
MUMBAI - In a stern signal intended to ensure product quality, the World Health Organization delisted combination vaccines made by Indian vaccine maker Panacea Biotec Ltd. from its list of pre-qualified suppliers
MUMBAI - India's vaccines specialist Bharat Biotech is reshaping prices of life-saving vaccines with the announcement that it will make available its rotavirus vaccine at $1 per dose for government supplies once it clears Phase III trials. Bharat Biotech expects the product to be market-ready in the next three years
Pfizer And GSK Use Novel Funding Mechanism To Send Blockbuster Vaccines To World's Poorest Countries
Pfizer and GlaxoSmithKline have agreed, after four years of negotiations, to supply their leading pneumococcal vaccines at significantly reduced prices to the world's poorest countries, signaling the first use of a novel funding mechanism that could create similar deals to bring new drugs to developing countries